Abstract: Apremilast, a small molecule that acts by inhibition of the phosphodiesterase-4 enzyme, has been approved for the management of plaque psoriasis in China. Utilizing‘apremilast’ as a keyword in the title, the PubMed database was searched for randomized controlled trial data on psoriatic arthritis, Behet's disease, vitiligo, alopecia and hidramatitis, and case reports of atopic dermatitis, Hailey-Hailey disease, hidradenitis suppurativata, dermatomyositis, systemic sclerosis, chronic actinic dermatitis and pyoderma gangrenosum treated with apremilast. Then we summarized the retrieved literature offering a reference for clinical practice.

Key words: apremilast, dermatosis, off-label use